Anti-Obesity Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers Global Anti Obesity Drugs Market Size & Statistics and It is Segmented by Mechanism of Action (Peripherally Acting Drugs and Centrally Acting Drugs), Drug Type (Prescription Drugs and OTC Drugs), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The Market Size and Forecasts are Provided in Terms of Value (USD Million) for the Above Segments.

Anti-Obesity Drugs Market Size

Anti-obesity Drugs Market Summary

Anti-Obesity Drugs Market Analysis

The Anti-obesity Drugs Market size is estimated at USD 9.26 billion in 2025, and is expected to reach USD 18.94 billion by 2030, at a CAGR of 15.37% during the forecast period (2025-2030).

During the COVID-19 situation, it was observed that obesity had increased exponentially. As per an article published by the European Journal of Nutrition in December 2020, the rate of obesity has increased in the world. The primary reason is a change in lifestyle and a decrease in exercise practice among people as they avoided gym and yoga classes due to the social distancing protocols. Similarly, according to the article published in Diabetes Obesity and Metabolism in August 2021, obesity prevalence is a significant and potentially modifiable risk factor for increased COVID-19 national caseload and mortality. This increased risk of the obese population leading to COVID-19 mortality which increased the demand for anti-obesity drugs during covid. However, increased awareness about healthy lifestyle and weight concerns during the pandemic are expected to maintain the demand of anti-obesity drugs even post-pandemic period.

According to the World Health Organization's report published in June 2021, 39 million children under the age of 5 years were overweight or obese in 2020. One in five children and adolescents globally is overweight. Incidences of obesity have been increasing fiercely over the past decades, and it is often described as a global endemic, especially in developed countries where lifestyle-related disorders, such as anxiety, stress, smoking, and drinking, are more prevalent. Owing to the increase in the obesity population worldwide, the key players in the market are initiating product developments and seeking market approvals. For instance, in January 2021, Novartis AG announced the results of its Phase II trial of the investigational product drug called Bimagrumab. The drug has shown potential for the indication of obesity. The drug is currently being studied in the Novartis pipeline. This may result in new treatment options, boosting market growth over the forecast period.

In addition, research on several potential drug molecules that target both obesity and Type 2 diabetes mellitus has become a key trend among the anti-obesity market players. The increasing epidemic of obesity and Type 2 diabetes is encouraging researchers and vendors in the market to research drugs that can counter both obesity and Type 2 diabetes. Hence, the increasing obese population, rise in unhealthy eating habits, and sedentary lifestyles are expected to drive the market growth over the forecast period.

However, the availability of alternative therapies and the potential side effects of anti-obesity drugs are expected to restrain the market growth.

Anti-Obesity Drugs Industry Overview

The anti-obesity drug market is moderated due to the presence of companies operating globally and regionally. The competitive landscape includes an analysis of a few international as well as local companies that hold a significant market share and are well known, including GlaxoSmithKline PLC, Novo Nordisk AS, Pfizer Inc., F. Hoffmann-La Roche AG, and Bayer AG.

Anti-Obesity Drugs Market Leaders

  1. Vivus

  2. F Hoffmann-La Roche AG

  3. GlaxoSmithKline PLC

  4. Novo Nordisk AS

  5. Currax Pharmaceuticals LLC

  6. *Disclaimer: Major Players sorted in no particular order
Anti-obesity Drugs Market Concentration
Need More Details on Market Players and Competitors?
Download PDF

Anti-Obesity Drugs Market News

  • June 2021: the United States Food and Drug Administration (FDA) approved Semaglutide 2.4 mg for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure or cholesterol, or T2D) for use in addition to a reduced-calorie diet and increased physical activity.
  • January 2021: Novo Nordisk AS signed a partnership with the startup Fauna Bio to identify new therapeutic approaches to obesity by studying the molecules and pathways that regulate metabolism in hibernating animals.

Anti-Obesity Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Obesity and Related Chronic Diseases
    • 4.2.2 Growing Unhealthy and Sedentary Lifestyles
  • 4.3 Market Restraints
    • 4.3.1 Availability of Alternative Treatment Options
    • 4.3.2 Side Effects of Drugs
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 By Mechanism of Action
    • 5.1.1 Peripherally Acting Drugs
    • 5.1.2 Centrally Acting Drugs
  • 5.2 By Drug Type
    • 5.2.1 Prescription Drugs
    • 5.2.2 OTC Drugs
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 United Kingdom
    • 5.3.2.2 Germany
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Alizyme
    • 6.1.2 Bayer AG
    • 6.1.3 Bristol-Myers Squibb
    • 6.1.4 Currax Pharmaceuticals LLC
    • 6.1.5 F. Hoffmann-La Roche AG
    • 6.1.6 GlaxoSmithKline PLC
    • 6.1.7 Merck & Co. Inc.
    • 6.1.8 Norgine BV
    • 6.1.9 Novo Nordisk AS
    • 6.1.10 Pfizer Inc.
    • 6.1.11 Rhythm Pharmaceuticals
    • 6.1.12 Takeda Pharmaceuticals
    • 6.1.13 Vivus Inc.
    • 6.1.14 Zafgan
    • 6.1.15 Zydus Cadila
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Anti-Obesity Drugs Industry Segmentation

As per the scope of the report, anti-obesity drugs or weight loss medications are pharmacological agents that reduce or control weight. These medications alter one of the fundamental processes of the human body, weight regulation, by altering either appetite or absorption of calories. The anti-obesity drugs market is segmented by mechanism of action (peripherally acting drugs and centrally acting drugs), drug type (prescription drugs and OTC drugs), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the market size and forecasts in value (USD million) for the above segments.

By Mechanism of Action Peripherally Acting Drugs
Centrally Acting Drugs
By Drug Type Prescription Drugs
OTC Drugs
Geography North America United States
Canada
Mexico
Europe United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa GCC
South Africa
Rest of Middle-East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Anti-Obesity Drugs Market Research FAQs

How big is the Anti-obesity Drugs Market?

The Anti-obesity Drugs Market size is expected to reach USD 9.26 billion in 2025 and grow at a CAGR of 15.37% to reach USD 18.94 billion by 2030.

What is the current Anti-obesity Drugs Market size?

In 2025, the Anti-obesity Drugs Market size is expected to reach USD 9.26 billion.

Who are the key players in Anti-obesity Drugs Market?

Vivus, F Hoffmann-La Roche AG, GlaxoSmithKline PLC, Novo Nordisk AS and Currax Pharmaceuticals LLC are the major companies operating in the Anti-obesity Drugs Market.

Which is the fastest growing region in Anti-obesity Drugs Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Anti-obesity Drugs Market?

In 2025, the North America accounts for the largest market share in Anti-obesity Drugs Market.

What years does this Anti-obesity Drugs Market cover, and what was the market size in 2024?

In 2024, the Anti-obesity Drugs Market size was estimated at USD 7.84 billion. The report covers the Anti-obesity Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Anti-obesity Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Anti-Obesity Drugs Industry Report

Statistics for the 2025 Anti-obesity Drugs market share, size and revenue growth rate, created by Mordor Intelligenceā„¢ Industry Reports. Anti-obesity Drugs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Anti-Obesity Drugs Market Report Snapshots

Compare market size and growth of Anti-obesity Drugs Market with other markets in Healthcare Industry

Anti-Obesity Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)